Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors.
Scisciola L, Taktaz F, Fontanella RA, Pesapane A, Surina, Cataldo V, Ghosh P, Franzese M, Puocci A, Paolisso P, Rafaniello C, Marfella R, Rizzo MR, Barbato E, Vanderheyden M, Barbieri M.
Scisciola L, et al. Among authors: rafaniello c.
Cardiovasc Diabetol. 2023 Feb 2;22(1):24. doi: 10.1186/s12933-023-01754-2.
Cardiovasc Diabetol. 2023.
PMID: 36732760
Free PMC article.